Currently, Vertex Pharmaceuticals, Inc [VRTX] is trading at $461.68, up 5.31%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRTX shares have gain 5.02% over the last week, with a monthly amount glided 15.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on January 30, 2025, when Wells Fargo downgraded its rating to a Equal Weight but kept the price target unchanged to $460 for it. Previously, H.C. Wainwright reaffirmed its Buy rating on December 20, 2024, and dropped its price target to $535. On December 19, 2024, downgrade downgraded it’s rating to Perform. Jefferies upgraded its rating to a Buy and increased its price target to $550 on December 09, 2024. Citigroup initiated its recommendation with a Buy and recommended $575 as its price target on November 14, 2024.
This stock has fluctuated between a low of $377.85 and a high of $519.88 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $508.91 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $461.68 at the most recent close of the market. An investor can expect a potential return of 10.23% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Trailing Twelve Months sales for Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] were 10.62B which represents 11.86% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.03%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 448.57 points at the first support level, and at 435.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 473.41, and for the 2nd resistance point, it is at 485.15.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] is 2.47. In addition, the Quick Ratio stands at 2.20 and the Cash Ratio stands at 1.32. Considering the valuation of this stock, the price to sales ratio is 11.20, the price to book ratio is 7.61.
Transactions by insiders
Recent insider trading involved ALTSHULER DAVID, EVP, Chief Scientific Officer, that happened on Nov 15 ’24 when 15.0 shares were sold. Officer, ALTSHULER DAVID completed a deal on Nov 15 ’24 to buy 15.0 shares. Meanwhile, EVP & Chief Financial Officer WAGNER CHARLES F JR sold 3000.0 shares on Nov 11 ’24.
